Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giulia Bon

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
Molecular Oncology|March 26, 2026
Hippo pathway at the crossroads of stemness and therapeutic resistance in breast cancerGiulia Schiavoni, Antonella Palmese, Stefano Scalera, et al.
Cancer Research|July 2, 2009
Negative regulation of beta4 integrin transcription by homeodomain-interacting protein kinase 2 and p53 impairs tumor progressionGiulia Bon, Selene E Di Carlo, Valentina Folgiero, et al.
Cell Cycle (Georgetown, Tex.)|April 17, 2014
miR-221/222 control luminal breast cancer tumor progression by regulating different targetsPatrizia Dentelli, Matteo Traversa, Arturo Rosso, et al.
Oncotarget|January 11, 2015
Sema6A and Mical1 control cell growth and survival of BRAFV600E human melanoma cellsRossella Loria, Giulia Bon, Valentina Perotti, et al.
Oncotarget|January 10, 2018
Dual targeting of HER3 and MEK may overcome HER3-dependent drug-resistance of colon cancersGiulia Bon, Rossella Loria, Carla Azzurra Amoreo, et al.
Plos One|February 14, 2008
Induction of ErbB-3 expression by alpha6beta4 integrin contributes to tamoxifen resistance in ERbeta1-negative breast carcinomasValentina Folgiero, Paolo Avetrani, Giulia Bon, et al.
Oncogene|July 8, 2018
HMGA1/E2F1 axis and NFkB pathways regulate LPS progression and trabectedin resistanceRossella Loria, Valentina Laquintana, Giulia Bon, et al.
Biology Open|September 6, 2014
CBX7 gene expression plays a negative role in adipocyte cell growth and differentiationFloriana Forzati, Antonella Federico, Pierlorenzo Pallante, et al.
Cancer Science|May 8, 2024
HER2 mutation as an emerging target in advanced breast cancerGiulia Bon, Francesca Sofia Di Lisa, Lorena Filomeno, et al.
Journal of Experimental & Clinical Cancer Research : CR|April 20, 2022
SEMA6A/RhoA/YAP axis mediates tumor-stroma interactions and prevents response to dual BRAF/MEK inhibition in BRAF-mutant melanomaRossella Loria, Valentina Laquintana, Stefano Scalera, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
Molecular Oncology|March 26, 2026
Hippo pathway at the crossroads of stemness and therapeutic resistance in breast cancerGiulia Schiavoni, Antonella Palmese, Stefano Scalera, et al.
Cancer Research|July 2, 2009
Negative regulation of beta4 integrin transcription by homeodomain-interacting protein kinase 2 and p53 impairs tumor progressionGiulia Bon, Selene E Di Carlo, Valentina Folgiero, et al.
Cell Cycle (Georgetown, Tex.)|April 17, 2014
miR-221/222 control luminal breast cancer tumor progression by regulating different targetsPatrizia Dentelli, Matteo Traversa, Arturo Rosso, et al.
Oncotarget|January 11, 2015
Sema6A and Mical1 control cell growth and survival of BRAFV600E human melanoma cellsRossella Loria, Giulia Bon, Valentina Perotti, et al.
Oncotarget|January 10, 2018
Dual targeting of HER3 and MEK may overcome HER3-dependent drug-resistance of colon cancersGiulia Bon, Rossella Loria, Carla Azzurra Amoreo, et al.
Plos One|February 14, 2008
Induction of ErbB-3 expression by alpha6beta4 integrin contributes to tamoxifen resistance in ERbeta1-negative breast carcinomasValentina Folgiero, Paolo Avetrani, Giulia Bon, et al.
Oncogene|July 8, 2018
HMGA1/E2F1 axis and NFkB pathways regulate LPS progression and trabectedin resistanceRossella Loria, Valentina Laquintana, Giulia Bon, et al.
Biology Open|September 6, 2014
CBX7 gene expression plays a negative role in adipocyte cell growth and differentiationFloriana Forzati, Antonella Federico, Pierlorenzo Pallante, et al.
Cancer Science|May 8, 2024
HER2 mutation as an emerging target in advanced breast cancerGiulia Bon, Francesca Sofia Di Lisa, Lorena Filomeno, et al.
Journal of Experimental & Clinical Cancer Research : CR|April 20, 2022
SEMA6A/RhoA/YAP axis mediates tumor-stroma interactions and prevents response to dual BRAF/MEK inhibition in BRAF-mutant melanomaRossella Loria, Valentina Laquintana, Stefano Scalera, et al.
Pageof 3